pI: 4.206 |
Length (AA): 631 |
MW (Da): 70741 |
Paralog Number:
0
Signal peptide: N | GPI Anchor: N | Predicted trans-membrane segments: 0
Targets have been classified into druggability groups (DG) according to their druggability score in network driven prioritizations. DGs range from 1 to 5; the higher the group number, the higher the chance of the target to be druggable
Modbase 3D models:
There are 6 models calculated for this protein. More info on
these models, including the
models themselves is available at:
Modbase
Target Beg | Target End | Template | Template Beg | Template End | Identity | Evalue | Model Score | MPQS | zDope |
---|---|---|---|---|---|---|---|---|---|
213 | 630 | 1w3b (A) | 15 | 393 | 14.00 | 0 | 1 | 0.74 | 0.28 |
315 | 426 | 1hxi (A) | 334 | 445 | 70.00 | 0 | 1 | 1.15 | -1.84 |
512 | 584 | 1na3 (A) | 5 | 77 | 27.00 | 0.000000000023 | 1 | 0.65 | -2.09 |
315 | 628 | 3cv0 (A) | 334 | 651 | 66.00 | 0 | 1 | 1.28222 | -1.06 |
459 | 540 | 5dse (A) | 746 | 827 | 28.00 | 0.055 | 0.97 | 0.630552 | -1.35 |
494 | 566 | 1elw (A) | 21 | 93 | 23.00 | 0.22 | 0.91 | 0.527289 | -1.02 |
Help me make sense of these data.
A more detailed description of these scores is available at the Modbase Model Evaluation Help Pages, and in the papers referenced therein.
PDB Structures:
Upregulation Percent | Ranking | Stage | Dataset |
---|---|---|---|
Upper 60-80% percentile | amastigotes, metacyclic. | Fernandes MC |
Fernandes MC | Dual Transcriptome Profiling of Leishmania-Infected Human Macrophages Reveals Distinct Reprogramming Signatures. |
Ortholog group members (OG5_128408)
Species | Accession | Gene Product |
---|---|---|
Arabidopsis thaliana | AT5G56290 | peroxisome biogenesis protein 5 |
Brugia malayi | Bm1_47095 | TPR Domain containing protein |
Candida albicans | CaO19.5640 | similar to S. cerevisiae PEX5 (YDR244W) receptor for peroxisomal targeting sequence 1 |
Candida albicans | CaO19.13085 | similar to S. cerevisiae PEX5 (YDR244W) receptor for peroxisomal targeting sequence 1 |
Caenorhabditis elegans | CELE_C34C6.6 | Protein PRX-5, isoform A |
Dictyostelium discoideum | DDB_G0286033 | peroxin 5 |
Drosophila melanogaster | Dmel_CG14815 | Peroxin 5 |
Entamoeba histolytica | EHI_179030 | hypothetical protein, conserved |
Homo sapiens | ENSG00000139197 | peroxisomal biogenesis factor 5 |
Leishmania braziliensis | LbrM.34.1340 | peroxisome targeting signal 1 receptor, putative |
Leishmania donovani | LdBPK_351430.1 | peroxisome targeting signal 1 receptor, putative |
Leishmania infantum | LinJ.35.1430 | peroxisome targeting signal 1 receptor, putative |
Leishmania major | LmjF.35.1420 | peroxisome targeting signal 1 receptor, putative |
Leishmania mexicana | LmxM.34.1420 | peroxisome targeting signal 1 receptor, putative |
Loa Loa (eye worm) | LOAG_07334 | TPR Domain containing protein |
Mus musculus | ENSMUSG00000005069 | peroxisomal biogenesis factor 5 |
Neospora caninum | NCLIV_031880 | TPR domain-containing protein, putative |
Oryza sativa | 4345945 | Os08g0500100 |
Saccharomyces cerevisiae | YDR244W | Pex5p |
Schmidtea mediterranea | mk4.012492.01 | PEX5-related protein |
Schmidtea mediterranea | mk4.019214.01 | PEX5-related protein |
Trypanosoma brucei gambiense | Tbg972.5.1520 | peroxisome targeting signal 1 receptor, putative |
Trypanosoma brucei | Tb927.5.1100 | peroxisome targeting signal 1 receptor |
Trypanosoma congolense | TcIL3000_5_910 | peroxisome targeting signal 1 receptor |
Trypanosoma cruzi | TcCLB.511181.90 | peroxisome targeting signal 1 receptor, putative |
Trypanosoma cruzi | TcCLB.508299.70 | peroxisome targeting signal 1 receptor, putative |
Toxoplasma gondii | TGME49_231870 | tetratricopeptide repeat-containing protein |
Gene/Ortholog | Organism | Phenotype | Source Study |
---|---|---|---|
Tb927.5.1100 | Trypanosoma brucei | significant loss of fitness in bloodstream forms (3 days) | alsford |
Tb927.5.1100 | Trypanosoma brucei | significant loss of fitness in bloodstream forms (6 days) | alsford |
Tb927.5.1100 | Trypanosoma brucei | no significant loss or gain of fitness in procyclic forms | alsford |
Tb927.5.1100 | Trypanosoma brucei | no significant loss or gain of fitness in differentiation of procyclic to bloodstream forms | alsford |
CELE_C34C6.6 | Caenorhabditis elegans | embryonic lethal | wormbase |
CELE_C34C6.6 | Caenorhabditis elegans | larval arrest | wormbase |
CELE_C34C6.6 | Caenorhabditis elegans | slow growth | wormbase |
TGME49_231870 | Toxoplasma gondii | Essentiality uncertain | sidik |
keio | Systematic single-gene knock-out mutants of E. coli K12 | The Keio Collection |
shigen | Profiling of E. coli Chromosome (PEC) | National Institute of Genetics, Japan |
blattner | Systematic mutagenesis of the E. coli (MG1655) genome | J Bacteriol 2004, 186:4921-4930 |
yeastgenome | Systematic deletion of yeast genes | Saccharomyces Genome Database |
nmpdr | Genome-scale essentiality datasets from published studies (M. tuberculosis) | National Microbial Pathogen Data Resource |
neb | C. elegans RNAi phenotypes | Data obtained from Wormbase WS150, curated by K. Chaudary and T. Carlow, New England Biolabs |
wormbase | C. elegans RNAi experiments | WormBase web site, http://www.wormbase.org, release WS170 |
alsford | High-throughput phenotyping using parallel sequencing of RNA interference targets in the African trypanosome | Genome Res 2011, 21:915-924 |
gerdes | Experimental determination and system-level analysis of essential genes in E. coli MG1655 | Gerdes et al., J Bacteriol. 2003 185:5673-84 |
Affected Entity | Phenotypic quality | Occurs in | Occurs at | Evidence | Observed in | Drugs/Inhibitors |
---|---|---|---|---|---|---|
growth (GO:0040007) | lethal (sensu genetics) (PATO:0000718) | single cell organism (CARO:0000064) | promastigote (BTO:0001124) | inferred from loss-of-function mutant phenotype (ECO:0000016) | Leishmania donovani | No drug identifiers listed for this gene. |
Annotator: | crowther@u.washington.edu. | Comment: | targeted double KO of the PEX5 gene could not be generated. | References: | 10788481 |
In TDR Targets, information about phenotypes that are caused by drugs, or by genetic manipulation of cells (e.g. gene knockouts or knockdowns) is manually curated from the literature. These descriptions help to describe the potential of the target for drug development. If no information is available for this gene or if the information is incomplete, this may mean that i) the papers containing this information either appeared after the curation effort for this organism was carried out or they were inadvertently missed by curators; or that ii) the curation effort for this organism has not yet started.
In any case, if you have information about papers containing relevant validation data for this target, please contact us.